Equities analysts forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will announce sales of $4.38 billion for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with estimates ranging from $4.29 billion to $4.42 billion. Teva Pharmaceutical Industries posted sales of $4.56 billion during the same quarter last year, which would suggest a negative year over year growth rate of 3.9%. The firm is scheduled to announce its next quarterly earnings report before the market opens on Wednesday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $17.28 billion for the current fiscal year, with estimates ranging from $17.19 billion to $17.32 billion. For the next financial year, analysts anticipate that the business will report sales of $17.08 billion, with estimates ranging from $16.59 billion to $17.75 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 7th. The company reported $0.56 EPS for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The business had revenue of $4.26 billion for the quarter, compared to the consensus estimate of $4.25 billion.

A number of analysts have weighed in on the company. Bank of America upgraded Teva Pharmaceutical Industries from an “underperform” rating to a “buy” rating in a report on Friday, January 3rd. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 target price for the company in a report on Tuesday, November 12th. ValuEngine lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 3rd. Wells Fargo & Co lowered their target price on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a report on Monday, September 30th. Finally, Gabelli upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have given a buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and an average target price of $10.64.

In other news, VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the completion of the sale, the vice president now owns 24,883 shares in the company, valued at approximately $261,022.67. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.49% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GFS Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 1.4% in the 4th quarter. GFS Advisors LLC now owns 70,500 shares of the company’s stock worth $691,000 after purchasing an additional 1,000 shares in the last quarter. Huntington National Bank lifted its stake in Teva Pharmaceutical Industries by 38.9% in the 4th quarter. Huntington National Bank now owns 4,624 shares of the company’s stock worth $45,000 after purchasing an additional 1,294 shares in the last quarter. CAPROCK Group Inc. lifted its stake in Teva Pharmaceutical Industries by 6.2% in the 3rd quarter. CAPROCK Group Inc. now owns 23,730 shares of the company’s stock worth $163,000 after purchasing an additional 1,378 shares in the last quarter. AdvisorNet Financial Inc lifted its stake in Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after purchasing an additional 1,525 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its stake in Teva Pharmaceutical Industries by 50.9% in the 3rd quarter. Pacer Advisors Inc. now owns 5,219 shares of the company’s stock worth $36,000 after purchasing an additional 1,760 shares in the last quarter. 53.38% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries stock traded down $0.42 during mid-day trading on Tuesday, reaching $10.20. 15,846,184 shares of the company were exchanged, compared to its average volume of 13,784,133. The business has a fifty day moving average of $9.78 and a 200 day moving average of $8.41. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89. The firm has a market cap of $11.60 billion, a P/E ratio of 4.72, a PEG ratio of 1.06 and a beta of 1.81. Teva Pharmaceutical Industries has a 12-month low of $6.07 and a 12-month high of $20.21.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What is meant by a buy rating?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.